

Supplementary table 1. Baseline characteristics of patients by disease

		RA			AS			PsA		
		Rem	No rem	P	Rem	No rem	P	Rem	No rem	P
No. of patients		30	1777		18	718		32	791	
Age (years), mean (SD)		58.9 (12.4)	54.8 (13.0)	0.086	36.8 (14.0)	47.2 (12.7)	<0001	49.0 (12.4)	49.4 (11.7)	0.823
Female sex, n (%)		26 (86.7)	1412 (79.5)	0.332	4 (22.2)	235 (32.7)	0.347	13 (40.6)	443 (56.0)	0.086
Age at diagnosis, mean (SD)		52.3 (11.4)	45.7 (13.7)	0.009	32.0 (12.3)	37.9 (13.4)	0.063	41.3 (12.9)	42.5 (12.3)	0.615
Disease duration, mean (SD)		6.6 (3.8)	9.0 (8.4)	0.113	4.8 (6.4)	9.3 (9.9)	0.057	7.6 (4.2)	7.0 (6.7)	0.589
Smoking, n and %	Non-smoker	27 (90.0)	1235 (69.5)	0.113	14 (77.8)	406 (56.5)	0.224	27 (84.4)	524 (66.2)	0.159
	Current	2 (6.7)	318 (17.9)		3 (16.7)	225 (31.3)		4 (12.5)	152 (19.2)	
	Ex-smoker	1 (3.3)	185 (10.4)		0 (0)	62 (8.6)		1 (3.1)	82 (10.4)	
Charlson Comorbidity Index, mean (SD)		2.2 (1.7)	2.3 (1.6)	0.951	1.2 (0.5)	1.8 (1.3)	0.033	1.8 (1.7)	1.9 (1.2)	0.847
Previous biologic, n (%)	First-line	15 (50.0)	987 (55.5)	0.545	14 (77.8)	443 (61.7)	0.165	18 (56.3)	478 (60.4)	0.636
	Second-line	15 (50.0)	790 (44.5)		4 (22.2)	275 (38.3)		14 (43.8)	313 (39.6)	
Concomitant csDMARD, n (%)	MTX	13 (56.5)	934 (72.3)	0.095	1 (9.1)	115 (29.8)	0.137	11 (50.0)	340 (70.0)	0.048
	LFN	7 (35.0)	460 (41.7)	0.547	0 (0)	18 (5.4)	0.430	4 (21.1)	150 (38.0)	0.136
	SSZ	1 (5.3)	58 (6.4)	0.837	4 (33.3)	74 (20.8)	0.298	0 (0)	37 (10.9)	0.128
Time on previous bDMARD, mean (SD)		59.3 (49.6)	23.3 (34.1)	<0.001	35.5 (23.0)	27.0 (32.8)	0.275	49.9 (35.8)	23.9 (34.3)	<0.001
Treatment at discontinuation, n (%)	TNF-i	22 (73.3)	1195 (67.2)	0.903	18 (100)	664 (92.5)	0.691	32 (100)	644 (81.4)	0.299
	IL6-i	3 (10.0)	193 (10.9)		0 (0)	1 (0.1)		0 (0)	0 (0)	
	CD20-i	2 (6.7)	187 (10.5)		0 (0)	0 (0)		0 (0)	0 (0)	
	JAK-i	0 (0)	68 (3.8)		0 (0)	0 (0)		0 (0)	2 (0.3)	
	IL17-i	0 (0)	0 (0)		0 (0)	52 (7.2)		0 (0)	57 (7.2)	
	IL12-23-i	0 (0)	0 (0)		0 (0)	1 (0.1)		0 (0)	27 (3.4)	
	PDE4-i	0 (0)	0 (0)		0 (0)	0 (0)		0 (0)	57 (7.2)	

	Abatacept	3 (10.0)	128 (7.2)		0 (0)	0 (0)		0 (0)	3 (0.4)	
	RF-positive, n (%)	9 (30.0)	772 (43.4)	0.424	-	-	-	-	-	-
	ACPA-positive, n (%)	3 (23.1)	729 (72.0)	<0.001	-	-	-	-	-	-
	HLA-B27-positive, n (%)	-	-	-	12 (66.7)	517 (72.0)	0.883	6 (18.8)	110 (13.9)	0.549
	Moderate-high activity at initiation of biologic *	2 (10.0)	208 (16.3)	0.446	3 (25.0)	113 (18.8)	0.589	4 (19.1)	127 (19.8)	0.931

Footnote to supplementary table 1. Data are shown as mean (standard deviation), except for categorical variables, where they are expressed as n (%).

RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic DMARD; tsDMARD: targeted synthetic DMARD; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibody.

*Moderate-high disease activity was defined as DAS28 \geq 3.2 or BASDAI \geq 4, depending on the disease.